image credit: Pixabay

Collaboration aims to reduce time and cost of cell and gene therapy development

August 20, 2020

The technology, which is being developed by MicrofluidX, could help manufacturers overcome major bottlenecks in the development of cell and gene therapies, as well as reduce the time and costs associated with bringing such treatments to market.

Whilst cell and gene therapies offer promising treatment options in disease areas with unmet clinical needs, reliable methods are still needed to manufacture these therapies to commercial levels.

Read More on EPM Magazine